Insmed Announces Upcoming Data Presentations at ICAAC/ICC 2015
22 Septembre 2015 - 2:46AM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the needs of patients with rare diseases today
reported new nontuberculous mycobacteria (NTM) lung disease
information and a pharmacokinetic analysis of ARIKAYCE™ (liposomal
amikacin for inhalation) will be presented at the 2015 joint
meeting of the Interscience Conference of Antimicrobial Agents and
Chemotherapy (ICAAC) and the International Congress of Chemotherapy
and Infection (ICC). ICAAC/ICC 2015 is taking place in San Diego,
California from September 17-21.
Summarized below are the poster titles and presentation times.
Full abstracts can be found on the ICAAC website at
http://www.icaac.org/.
Poster Title: Pharmacokinetic (PK) Evaluation
of Liposomal Amikacin for Inhalation (LAI) in Patients with
Treatment-refractory Nontuberculous Mycobacteria (NTM) Lung
InfectionLead Author: C. Rubino Poster
Number: A-012Date: Friday, September 18,
2015Session Time: 12:00-2:00 PMSession
Title: Clinical Pharmacology of Antiviral and
Antituberculosis Agents
Poster Title: Nontuberculous Mycobacteria Lung
Infections: Increasing Incidence of Diagnosis in Medicare Patients
at a US Health PlanLead Author: K. Abraham
Poster Number: C-669Date:
Saturday, September 19, 2015Session Time: 11:00
AM-1:00 PM PTSession Title: Trends in
Antimicrobial Resistance and Epidemiology of Streptococci,
Enterococci and some Miscellaneous Bacteria
The posters will be made available on the
company’s website after presentation at the meeting.
About Insmed
Insmed Incorporated is a global
biopharmaceutical company focused on the needs of patients with
rare diseases. The company is advancing a global phase 3 clinical
study of ARIKAYCE™ (liposomal amikacin for inhalation) in
nontuberculous mycobacteria (NTM) lung disease, a rare and often
chronic infection that can lead to progressive inflammation and
lung damage. There are no currently approved treatments for NTM in
the United States or European Union (EU). In the EU, the
company has filed a marketing authorization application seeking
approval of ARIKAYCE for use in patients with NTM, as well as in
cystic fibrosis patients with Pseudomonas aeruginosa lung
infections. Insmed’s earlier-stage pipeline includes INS1009, a
nebulized prodrug formulation of treprostinil that the company is
developing for the treatment of pulmonary arterial hypertension
(PAH), a chronic, life-threatening disorder characterized by
abnormally high blood pressure in the arteries between the heart
and lungs. To complement its internal research, Insmed actively
seeks in-licensing opportunities for a broad range of rare
diseases. For more information visit www.insmed.com.
Insmed Incorporated:
Susan Mesco
Head of Investor Relations
908-947-4326
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024